malignancies represent some of the most aggressive forms of cancer, and in many
cases, current therapeutic options are very limited. Thus, the goal of the
Hematologic Malignancies (HEME) Program is to define key biological features of
leukemia and related blood cancers and translate these findings into more
effective therapies for patients.
• Investigate the developmental, genetic and environmental drivers
• Study metabolic and signaling changes
• Develop novel therapeutic strategies
A wide variety of clinical trials are
available through the Hematologic Malignancies research program. Click here
to see which trials are currently enrolling adult participants. For more information
click the study identifier or search the identifier number at clinicaltrials.gov.
For pediatric clinical trials, please call 720-777-6740 or email email@example.com.